Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR-Sensitive Mutations Combined With Co-Mutations Advanced NSCLC

Clinical trial NCT06348927 · RECRUITING

Trial details

NCT number: NCT06348927
Sponsor: Hunan Province Tumor Hospital
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Non-Small Cell Lung Cancer

Start date: 2024-07-01
Primary completion: 2025-10-31
Enrollment: 52

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.